Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
The leading oncology meeting in Asia-Pacific is preparing to open its doors in a few days! Discover breakthroughs on the most prevalent cancer types in the region and multidisciplinary educational sessions, including the Pan Asian Adapted Guidelines Lectures.
The congress abstracts are now available: browse them and discover the outstanding scientific and educational programme!
Online application is open until 27 November 2022
Online application is open until 31 January 2023
The state-of-the-art in the diagnosis and management of cervical and endometrial cancers
Learn best practice recommendations for the treatment of this tumour type in this condensed, accessible format
New data on the impact of niraparib maintenance on the overall survival of Asian patients with platinum-sensitive relapsed ovarian cancer - join this real-time presentation and discussion with leading experts
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
With more than 2.2 million new cases and nearly 1.8 million deaths in 2020, lung cancer represents 11.4% of the 19,292,789 new cases of cancer worldwide and 18% of its mortality.
ESMO is pleased to announce expending further translation of the Patient Guides in the Korean language
Evidence for efficacy is based on the results from the Study 16113
ESMO would like to thank the Hanoi Oncology Hospital (HOH) for providing translation in the Vietnamese language
New indication concerns a combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not indicated
Exploratory cohort results from a phase II study in patients who had not received previously anti-HER2 treatment
FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx Assay as a companion diagnostic device
ESMO is pleased to announce first translation of the Patient Guides in the Thai language
Findings from the largest prospective, international cohort of patients with advanced non-small cell lung cancer who underwent ctDNA-guided treatment with longitudinal follow-up for survival
Evidence for efficacy is based on the results from the Study 16113
New indication concerns a combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not indicated
Exploratory cohort results from a phase II study in patients who had not received previously anti-HER2 treatment
FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx Assay as a companion diagnostic device
Findings from the largest prospective, international cohort of patients with advanced non-small cell lung cancer who underwent ctDNA-guided treatment with longitudinal follow-up for survival
New indication concerns the first-line treatment of biliary tract cancer
Findings from the secondary analysis of the GAP70+ study
Findings from the AGO-OVAR 17 BOOST study
Evidence for efficacy is based on the results from the POSEIDON study
Findings suggest that analysis of multiple prostate diagnostic biopsy cores, in contrast to frequent practice, may help reduce tumour mischaracterisation and identify genetic alterations relevant to personalised treatment
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
The ESMO Asia Congress 2022 will be held in person in Singapore and virtually between 2-4 December 2022.
The Molecular Analysis for Precision Oncology Congress 2022 (MAP) is the yearly appointment where leading experts discuss current and future challenges in the rapidly developing field of precision oncology, with the aim of identifying targetable alterations through molecular profiling, to provide the best possible personalised treatment.
Cancer doctors, care providers and payers need to get ready for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment
A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma
Significant improvement in progression free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumours
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies
Sustainability will be at the heart of many discussions at the ESMO Congress 2022 , as illustrated by the new results and initiatives spanning cancer prevention, early detection and treatment that were announced today during the opening press conference
ESMO and EONS announce the launch of the ground-breaking, Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer
The ESMO Congress 2022 will be held in person in Paris and virtually between 9-13 September 2022.
With more than 2.2 million new cases and nearly 1.8 million deaths in 2020, lung cancer represents 11.4% of the 19,292,789 new cases of cancer worldwide and 18% of its mortality.
The European Society for Medical Oncology (ESMO) has announced today that the winner of the ESMO Award for Immuno-Oncology 2022 is conferred on Nina Bhardwaj for her outstanding contribution to cancer immunology research.
ESMO has announced today the winners of the 2022 ESMO Society Awards.
ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.
ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people
Developed by the ESMO Precision Medicine Working Group, they provide guidance to medical oncologists on the use of circulating tumour DNA assays in clinical practice
The role of polygenic scores for stratified cancer prevention, and the genetic determinants for PSA levels to improve cancer screening utility will be debated during the sixth instalment in the World Cancer Report Updates webinar series.
This year, World Cancer Day is launching #CloseTheCareGap, a three-year campaign aiming to promote awareness, collaboration, and action for a more equitable future in cancer care.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
With modest progress being made in the gender balance of the oncology field in recent years, women continue to be underrepresented in leadership positions despite making up an increasing proportion of the oncology workforce.
From EBCC 2022:
Indirect trial comparison suggests an overall survival advantage with ribociclib over palbociclib in combination with endocrine therapy for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
A reflection on what financial conflict of interests do on single people and what system implications they may have
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Republic of Singapore
Republic of Singapore
Republic of Singapore
Republic of Singapore
Republic of Singapore
Switzerland
Virtual Meeting
Switzerland
Republic of Singapore
South Africa
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
